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Abstract
Objectives: Primary: To compare the effectiveness of intensive group and individual interventions for smoking
cessation in a primary health care setting; secondary: to identify the variables associated with smoking cessation.
Methods: Three-pronged clinical trial with randomisation at the individual level. We performed the following: an
intensive individual intervention (III), an intensive group intervention (IGI) and a minimal intervention (MI). Included
in the study were smokers who were prepared to quit smoking. Excluded from the study were individuals aged
less than 18 years or with severe mental conditions or terminal illnesses. The outcome measure was continued
abstinence at 12 months confirmed through CO-oximetry (CO). The analysis was based on intention to treat.
Results: In total, 287 smokers were recruited: 81 in the III, 111 in the IGI, and 95 in the MI. Continued abstinence at
12 months confirmed through CO was 7.4% in the III, 5.4% in the IGI, and 1% in the MI. No significant differences
were noted between III and MI on the one hand, and between IGI and MI on the other [RR 7.04 (0.9-7.2) and RR
5.1 (0.6-41.9), respectively]. No differences were noted between IGI and III [RR 0.7 (0.2-2.2)]. In multivariate analysis,
only overall visit length showed a statistically significant association with smoking cessation.
Conclusions: The effectiveness of intensive smoking interventions in this study was lower than expected. No
statistically significant differences were found between the results of individual and group interventions.
Trial registration number: ISRCTN32323770
Background
Tobacco smoking is the leading cause of preventable
death in developed countries. In Spain, more than 15%
of all deaths are linked to smoking [1]. Reducing the use
of tobacco is currently the most important public health
measure that developed countries can implement.
Because of their close contact with the public, primary
health care workers can play a key role in efforts to
reduce smoking.
From 1 to 3% of smokers quit smoking in six months
after brief counseling by a health professional, while
another 2% to 3% quit smoking with no help at all.
Thus, counseling is a moderately effective public health
intervention with a potentially large population impact
[2]. Better results can be obtained with longer
interventions [2]. Similarly, treatment with nicotine deri-
vatives or with certain antidepressants (bupropion or
nortriptyline) is effective [3,4] and doubles the chances
of quitting smoking when used in conjunction with
non-pharmacologic methods [5]. On smoker follow-up,
abstinence rates as high as 20% are seen [6]. Cognitive
behavior therapies [[7] and motivational interview tech-
niques have also proved effective in getting people to
quit smoking [8]. The combined use of all these smok-
ing cessation methods, known as multi-component or
intensive intervention [9], can lead to abstinence rates
as high as 30% a year [10].
So far, no one has been able to demonstrate whether
intensive group intervention is more effective than indi-
vidual intervention [7]. A clinical trial conducted in our
setting for the treatment of alcoholism showed group
therapy to be more effective than individual therapy * Correspondence: mramos@dgsanita.caib.es
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any medium, provided the original work is properly cited.[11]. As for smoking behavior, two studies in our coun-
try have compared both types of interventions. The first
was a clinical trial in which higher smoking cessation
rates were obtained after six months with the group
intervention than with the individual intervention, but
the observed differences were not statistically significant
[12]. The second was a quasi-experimental “pre-post”
study without a control group in a specialized smoking
cessation unit in which group therapy yielded a smoking
cessation rate of 39% at 12 months, or better than the
rate obtained in any study with the individual interven-
tion [13].
Primary health care workers have little time to spare.
Further study is needed to determine if group interven-
tion is more effective than individual intervention
because, if it turns out to be, implementing it as the
preferred intervention for helping people quit smoking
in health centers could save health care workers a con-
siderable amount of time.
This study has two objectives. Its primary objective is
to compare the effectiveness of intensive group and
individual interventions for smoking cessation in pri-
mary health care. Its secondary objective is to identify
the variables associated with smoking cessation.
Methods
Design
Three-pronged, randomized clinical trial in a primary
health care setting in Mallorca. We carried out the fol-
lowing: an intensive individual intervention (III) and an
intensive group intervention (IGI) as experimental
branches, and the standard minimal intervention (MI)
as the control branch.
Subjects
The study population was made up of smokers who
attended health centres. We established the following
inclusion criteria: individuals who smoked and who
were in the preparatory phase of smoking cessation in
accordance with Prochaska’s and Di Clemente’st r a n s -
theoretical model of health behaviour change [14]. A
prepared individual was defined as one who had
expressed the wish to quit smoking and who felt ready
to set a deadline for doing so not more than one month
into the future. Individuals less than 18 years or with
terminal illness or certain mental health conditions
(dementia and schizophrenia) were excluded.
We expected a smoking cessation rate at 12 months of
5% in the MI, 15% in the III and 25% in the IGI. The
sample size needed to detect a 10% difference in the
main outcome measure between intervention groups
with 5% precision in both directions, 80% power and a
95% confidence level was 199 subjects per intervention
group, or 597 in all.
Intervention
Three were conducted: III, IGI and MI. In all three,
pharmacological treatment with nicotine derivatives or
b u p r o p i o nw a so f f e r e da sa no p t i o na tt h ep h y s i c i a n ’s
discretion. Both the III and the IGI consisted of six vis-
its during which the following were provided: counsel-
ing, psychological support and standard follow-up.
Counseling and psychological support were based on
motivational interview techniques [15] that sought to:
(a) reinforce in the smoker the motivation to quit smok-
ing before D day (the day fixed for quitting by the smo-
ker) and (b) prevent relapses after smoking cessation.
Intensive interventions followed clinical guidelines
developed in the Balearic Islands [16,17]. Physicians and
nurses in the III and IGI received identical training on
how to implement intensive interventions, whereas
health workers in the MI received only the basic train-
ing that had been offered previously to all primary
health care workers on how to diagnose smoking addic-
tion and provide brief counseling. In all three groups
the intervention was carried out by the “microteam,”
composed of one physician and one nurse. These work-
ers distributed the visits among themselves as they saw
fit; all they were instructed to do was to conduct some
of the visits together.
Allocation method
An allocation concealment method based on the use of
sequentially-numbered, opaque, sealed envelopes was
used. All 40 health centers that existed in Mallorca at
the time were invited to participate in the study, and 10
agreed. A block of 60 envelopes (20 for III, 20 for IGI
and 20 for MI) was prepared in the central research
unit for each participating health centre and subse-
quently sent out.
In each health centre, all physicians and nurses could
recruit subjects, but only one “microteam” performed
the III, one the IGI and one the MI. Smokers who ful-
filled the inclusion and exclusion criteria were invited to
participate in the study. If they consented, they were
referred to the corresponding physician or nurse, who
had them sign the informed consent form. After signing
the form, patients picked an envelope at the admissions
desk for random allocation to one of the intervention
arms. Next, a visit with the doctor or nurse in the inter-
vention arm to which the patient was allocated was
scheduled, and the intervention was begun.
Once the intervention had ended, follow-up visits
were scheduled at one month, 2 months, 3 months, 6
months, 9 months and 12 months. If a patient missed a
follow-up visit, telephone follow-up was attempted. Case
recruitment began in March 2005 and finished in June
2006. Case follow-up started in March 2005 and ended
in August 2007.
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Page 2 of 6Main outcome measure
Continued abstinence at 12 months confirmed through
CO. Secondary outcome measures: Self-reported contin-
ued abstinence at 12 months; point abstinence at 12
months confirmed by CO-oximetry (CO) and self-
reported point abstinence at 12 months.
Other variables
At baseline, the following information was obtained: (a)
socio-demographic: age, sex, occupation and educational
level; (b) lifestyle-related: use of alcohol and other drugs,
practice of regular physical activity, fruit and vegetable
intake; (c) health-related: history of arterial hyperten-
sion, diabetes, hyperlipidemi a ,o b e s i t y ,a s t h m a ,C O P D ,
ischemic heart disease, stroke, peripheral blood vessel
disease, cancer and mental illness (type and use of psy-
chotropic agents); (d) tobacco-related: main reason for
wanting to quit smoking, number of cigarettes smoked
daily, age at which smoking began, level of dependency
as per Fagerström’s test, smoking among individuals clo-
sest to the patient, number of past attempts to quit
smoking, number of days of abstinence, strategy fol-
lowed during past attempts (with or without profes-
sional help and with or without drugs) and reasons for
relapse (weight gain, anxiety, insomnia, “smoking does
no harm,” etc.): (e) intervention-related: preferences in
c o n n e c t i o nw i t ht h et y p eo fi n t e r v e n t i o nt h e yw o u l d
have chosen had they been able to choose (individual,
group, or either), and the strength of the patient’s belief
that he/she could quit smoking (on a scale from 0 to
10). During the intervention, the following information
was obtained at each visit: the person in charge of con-
ducting it (physician, nurse or both), its length, the
number of cigarettes smoked, CO results, whether the
participant was taking anti-smoking drugs (nicotine
derivatives or bupropion) or not, and the strength of the
patient’s belief that he/she could quit smoking. Partici-
pants were classified as being on nicotine derivatives or
bupropion if they were on these drugs during any of the
intervention visits. At each follow-up visit, the number
of cigarettes smoked and CO values were obtained.
Statistical analysis
We used the chi squared test and the Anova and Krus-
kal-Wallis tests to ascertain whether randomization had
resulted in three comparable groups at baseline, and to
make comparisons across the three interventions. We
used the Kolmogoroff-Smirnoff test to check the contin-
uous variables for normal distribution.
For the main objective, the analysis was based on
intention to treat. Cases lost during the interventions or
lost to follow-up were treated as if they were still smo-
kers at 12 months. The study statistician was blinded to
the intervention allocation of the participants. Another
member of the research team repeated the analysis to
assess whether blinding was successful. Continued and
point abstinence rates, confirmed by CO and self-report,
were estimated. Relative risks were calculated for each
outcome measure, along with the reduction in absolute
risk and the number of individuals needed to treat
(NNT) to obtain a single case of smoking cessation. All
these measures are presented, along with their 95% con-
fidence intervals.
To pursue the secondary objective, a bivariate analysis
was performed to determine what variables were asso-
ciated with smoking cessation. The chi squared test for
qualitative variables and the Anova and Kruskal-Wallis
tests for quantitative variables were used. Multivariate
logistic regression was performed to determine if any
variables other than group allocation were also asso-
ciated with smoking cessation. Variables that yielded a
significance level of < 0.25 in the bivariate analysis were
selected by means of a backward LR. We evaluated at
each step the potential confounding effect of the vari-
ables eliminated along the way. Multivariate analysis was
repeated with forced entry of anti-smoking drugs into
the model, and no changes in the final model beta coef-
ficients were observed.
Statistical software SPSS 11.5 for Windows was used.
The study was performed with the approval of the
Balearic Islands Ethics Committee.
Results
We recruited 287 smokers: 81 in the III, 111 in the IGI,
and 95 in the MI. Participants showed similar character-
istics across all groups, both socio-demographically and
in lifestyle, clinical historya n ds m o k i n gb e h a v i o r( A d d i -
tional file 1). Statistically significant differences were
noted only with respect to their preferred interventions
and COPD prevalence. The three interventions differed
significantly (Additional file 2) in total number of visits;
overall length (in minutes), which was six times greater
in the IGI than in the III or MI; the health worker pri-
marily responsible for conducting it, who was the physi-
cian in the III; the nurse, alone or with a physician, in the
IGI; and the physician or nurse in the MI; and finally, the
use of drug therapy, which was low in all cases, although
it was highest in the MI, followed by the III, and lowest
in the IGI. No adverse effects were observed.
The flow of participants during the study is shown in
Figure 1. Less than half of those who participated in the
III and in the IGI completed the six intervention visits.
Follow-up at 12 months was completed in 25 (31%) of
cases in the III, 31 (28%) in the IGI and 23 (24%) in the
MI. Only 10 participants in the III, 11 in the IGI and 3
in the MI showed up at all follow-up visits (or could be
contacted by phone). CO was performed in 7 of the
patients in the III, 6 in the IGI and 1 in the MI.
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shows that higher abstinence rates at 12 months were
attained with the III than with the IGI and MI for each
outcome measure, although III’s superiority over the MI
was only statistically significant in the case of self-
reported continued abstinence and point abstinence
confirmed by CO.
No differences were observed between the IGI and the
III for continued abstinence confirmed by CO [RR 0.7
(0.2-2.2)] or for any of the other secondary outcome mea-
sures: self-reported continued abstinence [RR 0.8 (0.3-
2.2)]; point abstinence confirmed by CO [RR 0.5 (0.2-1.1)],
and self-reported point abstinence [RR 0.8 (0.4-1.8)].
Since self-reported point abstinence at 12 months was
t h eo u t c o m em e a s u r ef o rw h i c hw eh a dt h eg r e a t e s t
number of observations, we used it to determine if
other factors were also associated with smoking cessa-
tion in the study population. For this outcome measure,
the variables associated with smoking cessation in the
bivariate analysis are shown in Additional file 4. Such
variables were included in the multivariate analysis,
along with sex, educational level and type of interven-
tion. The final model chosen included, in addition to
the type of intervention, the overall length of the visits
and the number of past attempts to quit smoking. Only
overall visit length showed a statistically significant asso-
ciation with smoking cessation (Additional file 5).
Discussion
The results we obtained with intensive individual and
group interventions were worse than expected. We wish
to highlight two possible reasons for this: the lack of a
consistent definition for individuals in the preparatory
p h a s eb e f o r es m o k i n gc e s s a t i o n ,a n dt h es c a r c eu s eo f
drug therapy by health professionals.
Some individuals who were presumably in the pre-
paratory phase dropped out of the interventions after
the first visit or even before. This shows hat their level
of “preparedness” was low. The strategy employed to
ascertain preparedness status (asking individuals if they
felt prepared and able to fix a date to quit smoking)
may have been a poor one; it may have been better to
assess the smoker’s state of preparedness in greater
depth through an open interview. Nonetheless, the dif-
ferent stages of the process of change are known to fluc-
tuate [18]. In fact, authors such as Rollnick et al. [15]
have suggested that preparedness should be viewed as a
continuum along the process of smoking cessation
instead of a well-defined phase. Thus, we may have
incurred in selection bias by having used too simple a
method to identify individuals who were prepared to
quit smoking, whom we felt would be the ones to bene-
fit the most from an intensive intervention.
An unequal number of subjects in each trial arm,
together with differences among groups in subjects
treatment preferences, could be another source of selec-
tion bias. The trial arms were not balanced because
patients were unequally recruited among participating
health centers, not because they were included only
after being allocated to a trial arm that met their treat-
ment expectations. Actually, the number of subjects
who never attended an intervention visit after allocation
was 4 in III, 1 in IGI and 2 in MI. The percentage of
subjects who were allocated to an intervention in line
with their expectations may have been due to chance.
Drugs (nicotine derivatives or bupropion) were used
little during both individual and group interventions.
Primary health care physicians’ and nurses’ perceptions
of the effectiveness and safety of such treatments may
be worth exploring, since according to Vogt et al., they
may influence their prescription [19]. Perhaps not
enough emphasis was placed on the effectiveness and
benefits of drug therapy during health workers’ training.
It would have been a good idea, for instance, to provide
287 smokers
allocated
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287
Discontinued intervention
Figure 1 Case flow.
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York, where drugs were dispensed free of charge and
abstinence rates greater than 20% were attained at one
year [20]. On the other hand, the definition used for
“b e i n go nd r u gt h e r a p y ” - having been under treatment
during one of the intervention visits, whether continu-
ously or not - may explain why none of the individuals
being treated with nicotine derivatives quit smoking.
We do not feel the poor results obtained are part of
the described trend towards decreased effectiveness of
anti-smoking treatments bec a u s en o n - q u i t t e r sa r et h e
more recalcitrant individuals who never succeed in
shaking the addiction [21]. In our setting, the last
twenty years have seen a drop in smoking prevalence,
especially in males [22], although the prevalence rate
continues to be high, particularly among the lower
social classes [23]. In the Balearic Islands in particular,
33.7% of the men and 20.3% of the women report being
daily smokers [24].
Individual intervention yielded somewhat better
results than group intervention, which is six times as
long. This is precisely the disadvantage of group inter-
ventions, since a large percentage of patients drop out
i nt h ec o u r s eo ft h es e s s i o ns. As shown in this study,
h o w e v e r ,t h et i m ei n v e s t e db yh e a l t hw o r k e r sw a st h e
only factor associated with smoking cessation. Thus,
adherence to treatment is crucial, as already demon-
strated by other studies in which a dose-response rela-
tionship was found between the number of visits and a
successful outcome [25]. Studying why participants drop
out of sessions would be useful in trying to prevent
such losses and in learning to appropriately choose can-
didates for intensive interventions.
Based on our findings, no specific type of intervention
can be recommended to help smokers who attend
health centers to quit smoking. It is probably best for
health centers to provide group as well as individual
interventions, and minimal interventions in addition to
intensive ones. On the one hand, repeated minimal
intervention is very cost-effective [26]; on the other,
group intervention requires more available resources,
such as nursing staff. Individual intervention could be
reserved for smokers who demand individualized care
[27], although it is worth remembering that smokers
can quit smoking on their own and that health care
workers as well as public health officials should encou-
rage them to do so and pass laws restricting the use of
tobacco products in public spaces [28].
The study has two main limitations: non-attainment of
the estimated sample size and losses to follow-up.
We were unable to attain the desired sample size
because during the study more than 20% of participating
doctors and nurses were transferred to other health
centers. As a result, we had to identify new professionals
to recruit smokers and train them in conducting smok-
ing cessation interventions. Our study lacked sufficient
power to detect statistically significant differences
between the results of intensive individual and group
interventions, but the findings suggest that we were
wrong in our hypothesis that intensive group interven-
tion for smoking cessation is more effective than inten-
sive individual intervention.
When we compared self-reported point abstinence rates
with continued abstinence rates confirmed with CO, we
observed better results (12% for III, 10% for IGI and 6%
for MI compared with 7% for III, 5% for IGI and 1% for
MI). We consider self-reported point abstinence rates
more realistic and similar to those obtained in previous
studies. Although continuous abstinence is considered the
gold standard outcome for smoking cessation [29], some
studies have shown that smokers do not lie about their
smoking status when asked about it directly [30].
Patient follow-up presented additional difficulties, both
for patients who quit smoking and for those who did
not. Participants in the first group did not understand
why they had to continue visiting the health centre
since they had quit smoking already; those in the second
group felt embarrassed about not having been able to
quit. Poor compliance with follow-up visits made us
choose point self-reported smoking cessation as the out-
come measure for exploring other variables potentially
associated with having quit smoking.
Conclusions
Intensive smoking cessation interventions in this study
were less effective than expected. No statistically signifi-
cant differences could be shown between the results of
individual and group interventions. Further research is
needed on the effectiveness of combination treatments
to help individuals quit smoking in primary health care
settings.
Additional file 1: Group comparability before the intervention. The
data provided represent the characteristics of the participants in each
branch before the intervention.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2458-10-
89-S1.RTF]
Additional file 2: Group comparability after the intervention.T h e
data provided represent the characteristics of the intervention received
in each branch.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2458-10-
89-S2.RTF]
Additional file 3: Intervention effectiveness. The data provided
represent the outcome measures for the main objective of the study.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2458-10-
89-S3.RTF]
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Page 5 of 6Additional file 4: Variables associated with smoking cessation in the
bivariate analysis. The data provided represent the bivariate analysis for
the secondary objective.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2458-10-
89-S4.RTF]
Additional file 5: Variables associated with smoking cessation in the
multivariate analysis. The data provided represent the multivariat
analysis for the secondary objective.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2458-10-
89-S5.RTF]
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